<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang M</submitter><funding>Tai’shan Scholar Engineering Construction Fund of Shandong Province of China</funding><funding>Shandong University</funding><pagination>647611</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7947916</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Dental caries is an acid-related disease. Current anti-caries agents mainly focus on the bacteriostatic effect in a neutral environment and do not target acid-resistant microorganisms related to caries in acidic milieus.&lt;h4>Objectives&lt;/h4>To assess the &lt;i>in vitro&lt;/i> antibacterial activities of bedaquiline against oral pathogens in acidic milieus.&lt;h4>Methods&lt;/h4>&lt;i>Streptococcus mutans&lt;/i>, &lt;i>Streptococcus sanguinis&lt;/i>, and &lt;i>Streptococcus salivarius&lt;/i> were used to prepare the mono-/multiple suspension and biofilm. The MIC and IC&lt;sub>50&lt;/sub> of bedaquiline against &lt;i>S. mutans&lt;/i> were determined by the broth microdilution method. Bedaquiline was compared regarding (i) the inhibitory activity in pH 4-7 and at different time points against planktonic and biofilm; (</pubmed_abstract><journal>Frontiers in microbiology</journal><pubmed_title>&lt;i>In vitro&lt;/i> Antibacterial Activity of an FDA-Approved H&lt;sup>+&lt;/sup>-ATPase Inhibitor, Bedaquiline, Against &lt;i>Streptococcus mutans&lt;/i> in Acidic Milieus.</pubmed_title><pmcid>PMC7947916</pmcid><funding_grant_id>2018GN024</funding_grant_id><funding_grant_id>TS201511106</funding_grant_id><pubmed_authors>Zhang D</pubmed_authors><pubmed_authors>Zhou S</pubmed_authors><pubmed_authors>Yu W</pubmed_authors><pubmed_authors>Zhang M</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Zhang B</pubmed_authors><pubmed_authors>Lo ECM</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;i>In vitro&lt;/i> Antibacterial Activity of an FDA-Approved H&lt;sup>+&lt;/sup>-ATPase Inhibitor, Bedaquiline, Against &lt;i>Streptococcus mutans&lt;/i> in Acidic Milieus.</name><description>&lt;h4>Background&lt;/h4>Dental caries is an acid-related disease. Current anti-caries agents mainly focus on the bacteriostatic effect in a neutral environment and do not target acid-resistant microorganisms related to caries in acidic milieus.&lt;h4>Objectives&lt;/h4>To assess the &lt;i>in vitro&lt;/i> antibacterial activities of bedaquiline against oral pathogens in acidic milieus.&lt;h4>Methods&lt;/h4>&lt;i>Streptococcus mutans&lt;/i>, &lt;i>Streptococcus sanguinis&lt;/i>, and &lt;i>Streptococcus salivarius&lt;/i> were used to prepare the mono-/multiple suspension and biofilm. The MIC and IC&lt;sub>50&lt;/sub> of bedaquiline against &lt;i>S. mutans&lt;/i> were determined by the broth microdilution method. Bedaquiline was compared regarding (i) the inhibitory activity in pH 4-7 and at different time points against planktonic and biofilm; (</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2026-05-02T16:47:21.782Z</modification><creation>2021-03-14T08:17:18Z</creation></dates><accession>S-EPMC7947916</accession><cross_references><pubmed>33717046</pubmed><doi>10.3389/fmicb.2021.647611</doi></cross_references></HashMap>